v3.26.3
Note 1 - Nature of the Business and the Basis of Preparation
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Nature of Operations [Text Block]

1.

Nature of the business and the basis of preparation

 

BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on November 21, 2014. The Company and its subsidiaries (collectively, the “Group”) are principally engaged in clinical stage biopharmaceutical activities focused on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the “Founders”) since its incorporation.

 

In January 2025, the Company entered into definitive agreements with three investors to sell a portion of the Series A-1 Preferred Shares of SEED Therapeutics Inc. (“SEED”) owned by the Company for gross proceeds of approximately $35,418, in three closings. The first closing of 1,730,454 shares for approximately $7.35 million occurred in February 2025. The second closing of 3,103,055 shares for approximately $13.19 million, which was originally scheduled to occur no later than December 15, 2025, has not occurred. Under the terms of the definitive agreements, the third closing of 3,500,128 shares for approximately $14.88 million is scheduled to occur no later than December 15, 2026. There can be no assurance that the second or third closings will occur on the scheduled timeline or at all.

 

On June 29, 2026, BeyondSpring Australia Pty Ltd was incorporated in Australia as a wholly owned subsidiary of BeyondSpring Pharmaceuticals Inc.

 

On September 29, 2026, the Company entered into a sales agreement with Citizens JMP Securities, LLC (the “Agent”) to act as an agent in selling up to 9,200,000 of the Company’s ordinary shares in an at-the-market (“ATM”) offering program. As of September 30, 2026, the Company had issued 289,239 ordinary shares under the ATM Program and received aggregate net proceeds of $221, after deducting sales commissions.

 

On September 30, 2026, the Company sold all of its equity interests in BeyondSpring Ltd., a British Virgin Islands holding company, together with its direct and indirect subsidiaries and related investments (the “Sale”). BeyondSpring Ltd. indirectly held the Company’s interests in Dalian Wanchunbulin Pharmaceuticals Ltd., a limited liability company incorporated under the laws of the People’s Republic of China (“Bulin”), and in SEED through SEED Technology Limited. Upon completion of the Sale, the Company lost control of BeyondSpring Ltd. and its subsidiaries including Bulin, as well as SEED, and accordingly deconsolidated these entities on September 30, 2026. Following the sale, the Company holds approximately 29.14% of SEED’s outstanding shares. See Note 3 – Discontinued operations.

 

As of September 30, 2026, the subsidiaries of the Company are as follows:

 

Name of company

Place of incorporation

Date of incorporation

Percentage of ownership by the Group

Principal activities

         

BeyondSpring Pharmaceuticals Inc. (“BeyondSpring US”)

Delaware, U.S.

June 18, 2013

100%

Clinical trial activities

         

BeyondSpring Australia Pty Ltd

Australia

June 29, 2026

100%

Clinical trial activities

         

Wanchun Biotechnology Limited (“BVI Biotech”)

BVI

April 1, 2015

100%

Holding company

 

The accompanying condensed consolidated balance sheet as of September 30, 2026, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2025 and 2026, the condensed consolidated statements of shareholders’ equity (deficit) for the three and nine months ended September 30, 2025 and 2026, the condensed consolidated statements of cash flows for the nine months ended September 30, 2025 and 2026, and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the U.S., or U.S. GAAP, for interim financial information using accounting policies that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended December 31, 2025. Accordingly, these unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements.

 

In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Group for each of the periods presented. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of results to be expected for any other interim period or for the full year of 2026. The consolidated balance sheet as of December 31, 2025 was derived from the audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2025.

 

As described in Note 3, on September 30, 2026, the Company completed the Sale of BeyondSpring Ltd. and its subsidiaries, including Bulin. Accordingly, the BVI Disposal Group (as defined in Note 3) is presented as discontinued operations in accordance with ASC 205-20, and prior period amounts have been retrospectively recast as follows:

 

 

i.

The assets and liabilities of the BVI Disposal Group as of December 31, 2025 have been reclassified to current and noncurrent assets and liabilities of discontinued operations in the condensed consolidated balance sheet; and

 

ii.

The results of operations of the BVI Disposal Group for the three and nine months ended September 30, 2025 have been reclassified to net income (loss) from discontinued operations in the condensed consolidated statements of comprehensive income (loss).

 

SEED and its subsidiaries have been presented as discontinued operations since December 2024 and were not affected by this recast. The recast had no effect on previously reported consolidated net income (loss), total assets, total liabilities or total shareholders’ equity (deficit).